Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.

Lee SM, Upadhyay S, Lewanski C, Falk S, Skailes G, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Rudd R, Ngai Y, Edwards A, Hackshaw A.

Eur J Cancer. 2019 Sep 6;120:86-96. doi: 10.1016/j.ejca.2019.07.025. [Epub ahead of print]

2.

Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis.

Zhu Y, Wei Y, Zhang R, Dong X, Shen S, Zhao Y, Bai J, Albanes D, Caporaso NE, Landi MT, Zhu B, Chanock SJ, Gu F, Lam S, Tsao MS, Shepherd FA, Tardon A, Fernández-Somoano A, Fernandez-Tardon G, Chen C, Barnett MJ, Doherty J, Bojesen SE, Johansson M, Brennan P, McKay JD, Carreras-Torres R, Muley T, Risch A, Wichmann HE, Bickeboeller H, Rosenberger A, Rennert G, Saliba W, Arnold SM, Field JK, Davies MPA, Marcus MW, Wu X, Ye Y, Le Marchand L, Wilkens LR, Melander O, Manjer J, Brunnström H, Hung RJ, Liu G, Brhane Y, Kachuri L, Andrew AS, Duell EJ, Kiemeney LA, van der Heijden EH, Haugen A, Zienolddiny S, Skaug V, Grankvist K, Johansson M, Woll PJ, Cox A, Taylor F, Teare DM, Lazarus P, Schabath MB, Aldrich MC, Houlston RS, McLaughlin J, Stevens VL, Shen H, Hu Z, Dai J, Amos CI, Han Y, Zhu D, Goodman GE, Chen F, Christiani DC.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):935-942. doi: 10.1158/1055-9965.EPI-18-0356. Epub 2019 Jan 30.

PMID:
30700444
3.

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.

Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ, Gronchi A; EORTC – Soft Tissue and Bone Sarcoma Group.

Eur J Cancer. 2019 Mar;109:51-60. doi: 10.1016/j.ejca.2018.12.009. Epub 2019 Jan 25.

PMID:
30690293
4.

Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update.

Young RJ, Woll PJ.

Memo. 2017;10(4):190-193. doi: 10.1007/s12254-017-0365-x. Epub 2017 Nov 7. Review.

5.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S.

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

6.

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.

Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K.

Eur J Cancer. 2017 Sep;83:302-312. doi: 10.1016/j.ejca.2017.05.037. Epub 2017 Aug 4.

7.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team.

Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.

8.
9.

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.

Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C.

J Thorac Oncol. 2016 Sep;11(9):1511-21. doi: 10.1016/j.jtho.2016.05.028. Epub 2016 Jun 11.

10.

The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.

Lebret T, Casas A, Cavo M, Woll PJ, Deleplace C, Kennedy C, Schoen P, Jackisch C.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12490. Epub 2016 Apr 12.

11.

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ.

Invest New Drugs. 2016 Jun;34(3):290-9. doi: 10.1007/s10637-016-0336-9. Epub 2016 Mar 9.

12.

Eribulin in soft-tissue sarcoma.

Young RJ, Woll PJ.

Lancet. 2016 Apr 16;387(10028):1594-6. doi: 10.1016/S0140-6736(16)00162-8. Epub 2016 Feb 10. No abstract available.

13.

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.

Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Woll PJ, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G.

J Clin Oncol. 2016 Feb 10;34(5):488-94. doi: 10.1200/JCO.2015.64.0268. Epub 2015 Dec 23.

14.

The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study.

Danson SJ, Rowland C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton MQ, Woll PJ, Eiser C.

Support Care Cancer. 2016 Apr;24(4):1507-16. doi: 10.1007/s00520-015-2928-x. Epub 2015 Sep 12.

15.

Bone-targeted agents in the treatment of lung cancer.

Silva SC, Wilson C, Woll PJ.

Ther Adv Med Oncol. 2015 Jul;7(4):219-28. doi: 10.1177/1758834015582178. Review.

16.

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

O'Brien ME, Gaafar R, Hasan B, Menis J, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulias V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P; EORTC-LCG.

Eur J Cancer. 2015 Aug;51(12):1511-28. doi: 10.1016/j.ejca.2015.04.026. Epub 2015 Jun 11.

18.

Angiogenic growth factor expression in benign and malignant vascular tumours.

Young RJ, Fernando M, Hughes D, Brown NJ, Woll PJ.

Exp Mol Pathol. 2014 Aug;97(1):148-53. doi: 10.1016/j.yexmp.2014.06.010. Epub 2014 Jun 28.

PMID:
24984271
19.

Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium.

Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, Orlow I, Cox B; Cannabis and Respiratory Disease Research Group of New Zealand, Brhane Y, Liu G, Hung RJ.

Int J Cancer. 2015 Feb 15;136(4):894-903. doi: 10.1002/ijc.29036. Epub 2014 Jun 30.

20.

Quality of life, support and smoking in advanced lung cancer patients: a qualitative study.

Rowland C, Danson SJ, Rowe R, Merrick H, Woll PJ, Hatton MQ, Wadsley J, Ellis S, Crabtree C, Horsman JM, Eiser C.

BMJ Support Palliat Care. 2016 Mar;6(1):35-42. doi: 10.1136/bmjspcare-2013-000589. Epub 2014 Apr 30.

PMID:
24785651
21.

Vascular-targeted agents for the treatment of angiosarcoma.

Young RJ, Woll PJ, Staton CA, Reed MW, Brown NJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):259-70. doi: 10.1007/s00280-013-2345-0. Epub 2013 Nov 20.

PMID:
24253175
22.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H.

Support Care Cancer. 2014 Mar;22(3):679-87. doi: 10.1007/s00520-013-2022-1. Epub 2013 Oct 26.

23.

Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.

Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I.

J Thorac Oncol. 2012 Dec;7(12):1823-1829. doi: 10.1097/JTO.0b013e31826aec2b.

24.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C.

Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.

25.

Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.

Kasper B, Ouali M, van Glabbeke M, Blay JY, Bramwell VH, Woll PJ, Hohenberger P, Schöffski P.

Eur J Cancer. 2013 Jan;49(2):449-56. doi: 10.1016/j.ejca.2012.08.007. Epub 2012 Sep 10.

PMID:
22975215
26.

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee.

Lancet Oncol. 2012 Oct;13(10):1045-54. doi: 10.1016/S1470-2045(12)70346-7. Epub 2012 Sep 4.

PMID:
22954508
27.

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.

Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, Ulsperger E, Kerber A, Eckmayr J, von Pawel J.

Invest New Drugs. 2013 Feb;31(1):175-82. doi: 10.1007/s10637-012-9842-6. Epub 2012 Jul 3.

28.

Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.

Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, Spitz MR, Muscat JE, Rennert G, Aben KK, Andrew AS, Bencko V, Bickeböller H, Boffetta P, Brennan P, Brenner H, Duell EJ, Fabianova E, Field JK, Foretova L, Friis S, Harris CC, Holcatova I, Hong YC, Isla D, Janout V, Kiemeney LA, Kiyohara C, Lan Q, Lazarus P, Lissowska J, Le Marchand L, Mates D, Matsuo K, Mayordomo JI, McLaughlin JR, Morgenstern H, Müeller H, Orlow I, Park BJ, Pinchev M, Raji OY, Rennert HS, Rudnai P, Seow A, Stucker I, Szeszenia-Dabrowska N, Dawn Teare M, Tjønnelan A, Ugolini D, van der Heijden HF, Wichmann E, Wiencke JK, Woll PJ, Yang P, Zaridze D, Zhang ZF, Etzel CJ, Hung RJ.

Eur J Cancer. 2012 Sep;48(13):1957-68. doi: 10.1016/j.ejca.2012.01.038. Epub 2012 Mar 19.

29.

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.

Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ.

Br J Cancer. 2012 Mar 13;106(6):1153-9. doi: 10.1038/bjc.2012.50. Epub 2012 Feb 21.

30.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
31.

Angiosarcoma.

Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ.

Lancet Oncol. 2010 Oct;11(10):983-91. doi: 10.1016/S1470-2045(10)70023-1. Epub 2010 May 25. Review.

PMID:
20537949
32.

Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.

Lee SM, Rudd R, Woll PJ, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A.

J Clin Oncol. 2009 Nov 1;27(31):5248-54. doi: 10.1200/JCO.2009.21.9733. Epub 2009 Sep 21.

PMID:
19770378
33.

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A.

J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57. doi: 10.1093/jnci/djp200. Epub 2009 Jul 16.

PMID:
19608997
34.

Optimizing the yield and utility of circulating cell-free DNA from plasma and serum.

Xue X, Teare MD, Holen I, Zhu YM, Woll PJ.

Clin Chim Acta. 2009 Jun 27;404(2):100-4. doi: 10.1016/j.cca.2009.02.018. Epub 2009 Mar 10.

35.

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.

Hughes AN, O'Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, Price A.

J Clin Oncol. 2009 Mar 10;27(8):1220-6. doi: 10.1200/JCO.2008.19.3995. Epub 2009 Jan 21.

36.

Raised serum urea predicts for early death in small cell lung cancer.

Winter MC, Potter VA, Woll PJ.

Clin Oncol (R Coll Radiol). 2008 Dec;20(10):745-50. doi: 10.1016/j.clon.2008.09.001. Epub 2008 Oct 8.

PMID:
18845424
37.

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.

Din OS, Woll PJ.

Ther Clin Risk Manag. 2008 Feb;4(1):149-62.

38.

Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.

Zhu YM, Azahri NS, Yu DC, Woll PJ.

BMC Cancer. 2008 Jul 31;8:218. doi: 10.1186/1471-2407-8-218.

39.

Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom.

Gerrand CH, Billingham LJ, Woll PJ, Grimer RJ.

Sarcoma. 2007;2007:34128. doi: 10.1155/2007/34128.

40.

Genomic tests: unreliable for cancer? A focus on circulating DNA and lung cancer.

Teare MD, Woll PJ.

Expert Rev Mol Diagn. 2007 Nov;7(6):699-702. Review. No abstract available.

PMID:
18020899
41.

Circulating DNA and lung cancer.

Xue X, Zhu YM, Woll PJ.

Ann N Y Acad Sci. 2006 Sep;1075:154-64. Review.

PMID:
17108206
42.
43.
44.

Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer.

Zhu YM, Bagstaff SM, Woll PJ.

Br J Cancer. 2006 Jun 19;94(12):1936-41. Epub 2006 May 23.

45.

Mitogenic effects of interleukin-8/CXCL8 on cancer cells.

Zhu YM, Woll PJ.

Future Oncol. 2005 Oct;1(5):699-704. Review.

PMID:
16556047
46.

Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.

Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N.

J Natl Cancer Inst. 2005 May 4;97(9):666-74. Erratum in: J Natl Cancer Inst. 2005 Jun 15;97(12):941.

PMID:
15870437
47.

Roles for USF-2 in lung cancer proliferation and bronchial carcinogenesis.

Ocejo-Garcia M, Baokbah TA, Ashurst HL, Cowlishaw D, Soomro I, Coulson JM, Woll PJ.

J Pathol. 2005 Jun;206(2):151-9.

PMID:
15856526
48.

Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.

Zhu YM, Webster SJ, Flower D, Woll PJ.

Br J Cancer. 2004 Nov 29;91(11):1970-6.

49.

Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases.

Khan S, Coulson JM, Woll PJ.

Int J Cancer. 2004 Jul 20;110(6):891-5.

50.

Neuroendocrine phenotype of small cell lung cancer.

Coulson JM, Ocejo-Garcia M, Woll PJ.

Methods Mol Med. 2003;74:61-73. Review.

PMID:
12415686

Supplemental Content

Support Center